PE20021095A1 - Sal citrato de 5,8,14-triazatetraciclo[10.3.1.0.0]hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma - Google Patents

Sal citrato de 5,8,14-triazatetraciclo[10.3.1.0.0]hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma

Info

Publication number: PE20021095A1
Authority: PE; Peru
Prior art keywords: triazatetraciclo; hexadeca; pentaeno; same; pharmaceutical compositions
Prior art date: 2001-05-14

Application number

PE2002000392A

Other languages

English (en)

Spanish (es)

Inventor

Phillip James Johnson

Lewin Thoephilus Wint

Glenn Robert Williams

Peter Robert Rose

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-14

Filing date

2002-05-10

Publication date

2002-12-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23117854&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20021095(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-05-10 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2002-12-14 Publication of PE20021095A1 publication Critical patent/PE20021095A1/es

Links

KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title 1
150000003839 salts Chemical class 0.000 title 1
238000000034 method Methods 0.000 abstract 2
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 abstract 1
238000002441 X-ray diffraction Methods 0.000 abstract 1
150000001860 citric acid derivatives Chemical class 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
238000005388 cross polarization Methods 0.000 abstract 1
238000000354 decomposition reaction Methods 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
230000005855 radiation Effects 0.000 abstract 1
239000007787 solid Substances 0.000 abstract 1
230000007704 transition Effects 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Addiction (AREA)
Virology (AREA)
Diabetes (AREA)
Psychology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Oncology (AREA)
Obesity (AREA)
Hematology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Child & Adolescent Psychology (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Toxicology (AREA)

PE2002000392A 2001-05-14 2002-05-10 Sal citrato de 5,8,14-triazatetraciclo[10.3.1.0.0]hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma PE20021095A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US29086301P	2001-05-14	2001-05-14

Publications (1)

Publication Number	Publication Date
PE20021095A1 true PE20021095A1 (es)	2002-12-14

Family

ID=23117854

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PE2002000392A PE20021095A1 (es)	2001-05-14	2002-05-10	Sal citrato de 5,8,14-triazatetraciclo[10.3.1.0.0]hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma

Country Status (37)

Country	Link
US (1)	US6787549B2 (2)
EP (1)	EP1390366B1 (2)
JP (1)	JP4137645B2 (2)
KR (1)	KR20040008175A (2)
CN (1)	CN1509288A (2)
AP (1)	AP1429A (2)
AR (1)	AR035889A1 (2)
AT (1)	ATE303386T1 (2)
BG (1)	BG108344A (2)
CA (1)	CA2446988A1 (2)
CZ (1)	CZ20032917A3 (2)
DE (1)	DE60205888T2 (2)
DO (1)	DOP2002000390A (2)
DZ (1)	DZ3503A1 (2)
EA (1)	EA005529B1 (2)
EE (1)	EE200300557A (2)
ES (1)	ES2245731T3 (2)
GT (1)	GT200200081A (2)
HR (1)	HRP20030911A2 (2)
HU (1)	HUP0304085A3 (2)
IL (1)	IL157874A0 (2)
IS (1)	IS6956A (2)
MA (1)	MA27021A1 (2)
MX (1)	MXPA03010365A (2)
MY (1)	MY134123A (2)
NO (1)	NO20035035D0 (2)
NZ (1)	NZ528209A (2)
OA (1)	OA12600A (2)
PA (1)	PA8545001A1 (2)
PE (1)	PE20021095A1 (2)
PL (1)	PL366774A1 (2)
SK (1)	SK13372003A3 (2)
TN (1)	TNSN03112A1 (2)
UA (1)	UA73421C2 (2)
UY (1)	UY27287A1 (2)
WO (1)	WO2002092597A1 (2)
ZA (1)	ZA200307234B (2)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69839131T3 (de) *	1997-12-31	2015-05-07	Pfizer Products Inc.	Arylkondensierte azapolycyclische derivate
ATE356625T1 (de) *	2001-11-30	2007-04-15	Pfizer Prod Inc	Orale pharmazeutische zusammensetzungen mit verzögerter freisetzung enthaltend 5,8,14- triazatetracyclo (10.3.1.0(2,11) 0 (4,9) )- hexadeca-2(11) 3, 5,7, 9-pentaene
BRPI0410219A (pt) *	2003-05-20	2006-05-09	Pfizer Prod Inc	composições farmacêuticas de vareniclina
US20050043407A1 (en) *	2003-08-22	2005-02-24	Pfizer Inc	Pharmaceutical composition for the prevention and treatment of addiction in a mammal
BRPI0718600A2 (pt) *	2006-11-09	2013-12-10	Pfizer Prod Inc	Polimorfos de intermediários nicotínicos.
US8440825B2 (en)	2008-03-06	2013-05-14	Medichem S.A.	Fumaric acid salt of varenicline
EP2268639A2 (en)	2008-05-22	2011-01-05	Teva Pharmaceutical Industries Ltd.	Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318460A1 (en) *	2008-05-26	2009-12-24	Glenmark	Amorphous varenicline tartrate and process for the preparation thereof
WO2009155403A2 (en) *	2008-06-19	2009-12-23	Teva Pharmaceutical Industries Ltd.	Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) *	2008-07-10	2010-01-14	Revital Lifshitz-Liron	Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
NZ593223A (en) *	2008-12-11	2013-08-30	Cell Therapeutics Inc	11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1 (2,6).1(8, 12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
US20100189791A1 (en)	2009-01-23	2010-07-29	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline malate formulation
CA2801842A1 (en)	2009-06-10	2010-12-16	Actavis Group Ptc Ehf	Amorphous varenicline tartrate co-precipitates
EP2438054A1 (en)	2009-06-22	2012-04-11	Teva Pharmaceutical Industries Ltd.	Solid states forms of varenicline salts and processes for preparation thereof
WO2011140431A1 (en)	2010-05-06	2011-11-10	Teva Pharmaceutical Industries Ltd.	Varenicline salts and crystal forms thereof
JP5925381B2 (ja)	2012-04-13	2016-05-25	▲連雲▼港金康和信▲薬業▼有限公司ＬｉａｎｙｕｎｇａｎｇＪｉｎｋａｎｇＨｅｘｉｎＰｈａｒｍａｃｅｕｔｉｃａｌＣｏ．，Ｌｔｄ．	化合物［４−（２−アミノ−１０−メチル−４−オキソ−６，７，８，９−テトラヒドロ−４ａ，７−エピミノピリミド［４，５−ｂ］［１，４］ジアゼピン−５（４Ｈ）−イル）ベンゾイル］−グルタメート及びその製造
WO2018154395A2 (en)	2018-06-11	2018-08-30	Alvogen Malta Operations (Row) Ltd	Controlled release pharmaceutical composition of varenicline
EP3756653A1 (en) *	2019-06-28	2020-12-30	Alfred E. Tiefenbacher (GmbH & Co. KG)	Microparticulate varenicline citrate
WO2021188563A1 (en) *	2020-03-16	2021-09-23	Chengdu Scimount Pharmatech Co., Ltd.	5-ht3 receptor modulator, the crystalline form, methods of making, and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69839131T3 (de) *	1997-12-31	2015-05-07	Pfizer Products Inc.	Arylkondensierte azapolycyclische derivate
IL137937A0 (en) *	1999-08-27	2001-10-31	Pfizer Prod Inc	A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal

2002
- 2002-04-26 NZ NZ528209A patent/NZ528209A/en unknown
- 2002-04-26 OA OA1200300290A patent/OA12600A/en unknown
- 2002-04-26 ES ES02724553T patent/ES2245731T3/es not_active Expired - Lifetime
- 2002-04-26 CN CNA028099117A patent/CN1509288A/zh active Pending
- 2002-04-26 IL IL15787402A patent/IL157874A0/xx unknown
- 2002-04-26 DO DO2002000390A patent/DOP2002000390A/es unknown
- 2002-04-26 PL PL02366774A patent/PL366774A1/xx not_active Application Discontinuation
- 2002-04-26 KR KR10-2003-7014752A patent/KR20040008175A/ko not_active Ceased
- 2002-04-26 AT AT02724553T patent/ATE303386T1/de not_active IP Right Cessation
- 2002-04-26 CA CA002446988A patent/CA2446988A1/en not_active Abandoned
- 2002-04-26 HU HU0304085A patent/HUP0304085A3/hu unknown
- 2002-04-26 SK SK1337-2003A patent/SK13372003A3/sk unknown
- 2002-04-26 EA EA200301120A patent/EA005529B1/ru not_active IP Right Cessation
- 2002-04-26 JP JP2002589481A patent/JP4137645B2/ja not_active Expired - Fee Related
- 2002-04-26 DZ DZ023503A patent/DZ3503A1/fr active
- 2002-04-26 DE DE60205888T patent/DE60205888T2/de not_active Expired - Fee Related
- 2002-04-26 CZ CZ20032917A patent/CZ20032917A3/cs unknown
- 2002-04-26 EE EEP200300557A patent/EE200300557A/xx unknown
- 2002-04-26 MX MXPA03010365A patent/MXPA03010365A/es active IP Right Grant
- 2002-04-26 UA UA20031110265A patent/UA73421C2/uk unknown
- 2002-04-26 EP EP02724553A patent/EP1390366B1/en not_active Expired - Lifetime
- 2002-04-26 HR HR20030911A patent/HRP20030911A2/xx not_active Application Discontinuation
- 2002-04-26 WO PCT/IB2002/001450 patent/WO2002092597A1/en not_active Ceased
- 2002-05-06 US US10/139,449 patent/US6787549B2/en not_active Expired - Fee Related
- 2002-05-09 GT GT200200081A patent/GT200200081A/es unknown
- 2002-05-09 AP APAP/P/2002/002522A patent/AP1429A/en active
- 2002-05-10 PE PE2002000392A patent/PE20021095A1/es not_active Application Discontinuation
- 2002-05-13 AR ARP020101735A patent/AR035889A1/es unknown
- 2002-05-13 UY UY27287A patent/UY27287A1/es not_active Application Discontinuation
- 2002-05-13 MY MYPI20021725A patent/MY134123A/en unknown
- 2002-05-14 PA PA20028545001A patent/PA8545001A1/es unknown
2003
- 2003-07-08 TN TNPCT/IB2002/001450A patent/TNSN03112A1/fr unknown
- 2003-09-15 IS IS6956A patent/IS6956A/is unknown
- 2003-09-16 ZA ZA200307234A patent/ZA200307234B/en unknown
- 2003-11-10 MA MA27390A patent/MA27021A1/fr unknown
- 2003-11-11 BG BG108344A patent/BG108344A/bg unknown
- 2003-11-13 NO NO20035035A patent/NO20035035D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
DE60205888D1 (de)	2005-10-06
DZ3503A1 (2)	2002-11-21
KR20040008175A (ko)	2004-01-28
US20030149091A1 (en)	2003-08-07
EP1390366A1 (en)	2004-02-25
TNSN03112A1 (fr)	2005-12-23
IL157874A0 (en)	2004-03-28
DE60205888T2 (de)	2006-07-06
AR035889A1 (es)	2004-07-21
EE200300557A (et)	2004-04-15
MA27021A1 (fr)	2004-12-20
AP2002002522A0 (en)	2002-06-30
UY27287A1 (es)	2003-02-28
UA73421C2 (en)	2005-07-15
OA12600A (en)	2006-06-09
PA8545001A1 (es)	2003-09-05
NZ528209A (en)	2004-09-24
CZ20032917A3 (cs)	2004-07-14
ATE303386T1 (de)	2005-09-15
CA2446988A1 (en)	2002-11-21
GT200200081A (es)	2003-04-22
DOP2002000390A (es)	2003-03-15
PL366774A1 (en)	2005-02-07
US6787549B2 (en)	2004-09-07
EA005529B1 (ru)	2005-04-28
HUP0304085A2 (en)	2004-04-28
ZA200307234B (en)	2004-09-16
MY134123A (en)	2007-11-30
EA200301120A1 (ru)	2004-02-26
HRP20030911A2 (en)	2004-02-29
CN1509288A (zh)	2004-06-30
EP1390366B1 (en)	2005-08-31
HUP0304085A3 (en)	2005-09-28
JP4137645B2 (ja)	2008-08-20
MXPA03010365A (es)	2004-03-16
ES2245731T3 (es)	2006-01-16
AP1429A (en)	2005-06-13
BG108344A (bg)	2004-12-30
IS6956A (is)	2003-09-15
NO20035035L (no)	2003-11-13
JP2004529186A (ja)	2004-09-24
WO2002092597A1 (en)	2002-11-21
NO20035035D0 (no)	2003-11-13
SK13372003A3 (sk)	2004-08-03

Legal Events

Date	Code	Title	Description
2005-12-16	FD	Application declared void or lapsed

Publication	Publication Date	Title
PE20021095A1 (es)	2002-12-14	Sal citrato de 5,8,14-triazatetraciclo[10.3.1.0.0]hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma
CA2997310C (en)	2021-05-04	Oral care compositions and methods of use
Sobczyński et al.	2013	Influence of aqueous media properties on aggregation and solubility of four structurally related meso-porphyrin photosensitizers evaluated by spectrophotometric measurements
ES2659541T3 (es)	2018-03-16	Compuestos y composiciones novedosas para direccionar hacia células madre del cáncer
US8232417B1 (en)	2012-07-31	Artemisinin derivatives with natural amino acids, peptides, and amino sugars for skin imperfections and infection in mammals
US8193376B2 (en)	2012-06-05	Artemisinin derivatives with natural amino acids, peptides, and amino sugars for the treatment of infection and topical condition in mammals
ATE159010T1 (de)	1997-10-15	Substituierte (5,6)- dihydronaphthalinylverbindungen mit retinoid- artiger wirkung
BR0314338A (pt)	2005-07-05	Substância cristalina para medicamento oral sólido e medicamento oral sólido para o tratamento de disúria contendo a mesma
ES2632941T3 (es)	2017-09-18	Coprecipitado de uno o más polifenoles estilbénicos en sólidos aniónicos laminares, sus aplicaciones y método de preparación relacionado
DK0498069T3 (da)	1995-12-04	Ny anvendelse af peptidderivat
EP1362846A4 (en)	2006-10-04	AMINOETHANOL DERIVATIVES
BR0003075A (pt)	2001-03-13	Derivados de triazol e imidazol
BR112015002390B1 (pt)	2020-03-24	Derivados do ácido 5-aminolevulínico (5-ala), sua composição e seu uso como agentes fotossensibilizantes
SE9901573D0 (sv)	1999-05-03	New compounds
IT1144033B (it)	1986-10-29	Derivati triciclici e loro sali farmacologicamente attivi e composizioni farmaceutiche che li contengono,nonche' procedimento per la loro preparazione
CR20250146A (es)	2025-05-26	Enlazadores-cargas útiles de adc derivados de exatecán, composiciones farmacéuticas, y usos de los mismos
DK0570294T3 (da)	1998-02-02	2-formylpyridinthiosemicarbazonderivater, deres fremstilling og deres anvendelse som antitumormiddel
IT1229477B (it)	1991-09-03	Impiego di 5' deossi - 5' metiltioadenosina, s adenosilmetionina e dei loro sali per la preparazione di composizioni farmaceutiche atte a ridurre la seborrea e composizioni farmaceutiche relative
CA2959756C (en)	2023-02-28	Topical pterostilbene compositions for use in treating uv-induced loss of barrier function in skin
UY26720A1 (es)	2001-11-30	Derivados del pirrol
CR6561A (es)	2005-04-04	Sal polimorfica como un farmaco anti-migrana
US20240091115A1 (en)	2024-03-21	Oral Care Compositions and Methods of Use
IT9019793A0 (it)	1990-03-23	Composizioni farmaceutiche contenenti ipriflavone,procedimento per la loro preparazione e relativo impiego terapeutico
FI903692A0 (fi)	1990-07-20	Salter av n5, n10-metylen-5,6,7,8- tetrahydrofolsyra.
CN213191393U (zh)	2021-05-14	一种杀菌消毒装置